Intuitive Surgical
ISRG · What the business does, what can go wrong, and how options sellers approach it
What it does
Intuitive Surgical makes the da Vinci robotic surgical system. A surgeon sits at a console and controls small instruments that enter the patient through tiny incisions. The goal is minimally invasive surgery, which can mean smaller cuts and, for many procedures, shorter hospital stays than open surgery.
The company also makes the Ion system, used for lung biopsies, along with the instruments, accessories, software and training that surround its platforms.
How it makes money
Intuitive earns revenue in a few ways:
- Systems: hospitals buy or lease the robots.
- Instruments and accessories: many items are single-use or have a limited number of uses, so they are bought again with each procedure.
- Service: hospitals pay for maintenance and support contracts.
Because the installed base of systems keeps generating procedure-linked sales, a large share of revenue tends to recur. Robot placements matter, but procedure volume matters more over time.
Why investors own it
Investors often see Intuitive as a leader in robotic-assisted surgery. Common reasons include recurring instrument revenue, years of surgeon training and clinical evidence, switching costs once hospital teams are trained on a platform, and room to expand into new procedures and countries. It is in the S&P 500 and the Nasdaq-100.
What can go wrong
- Competition from other surgical robotics makers could pressure pricing and share.
- Hospital budgets and capital spending can slow system purchases.
- Procedure volumes can fall if patients delay elective surgery.
- Regulators, product recalls or safety concerns can disrupt sales and reputation.
- Tariffs, reimbursement changes and supply chain problems can squeeze margins.
- The stock has often carried a premium valuation, so disappointments can hit the share price hard.
What to watch
- Procedure growth, in the US and internationally
- New da Vinci system placements and the installed base
- Instrument and accessory revenue per procedure
- Gross margin trends
Options income angle
Options on ISRG are typically liquid. Implied volatility tends to rise ahead of quarterly earnings and around news on procedures, competition or regulation, then often drops after results.
One caution for premium sellers: the stock can move sharply on earnings, and a large gap can overwhelm the premium collected.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Intuitive Surgical's 2025 was a year of strong growth. Total revenue increased by 21% to $10.1 billion, and operating income increased by 25% to $2.95 billion. Margins slipped as tariffs and new factory costs weighed on gross profit. The filing also flags weaker system placements in China and a growing share of revenue tied to leases that depend on how often hospitals use the machines.
How the business did
- Revenue rose in every line. Instruments and accessories (the single-use tools bought with each surgery) increased by 19% to $6.02 billion, and systems revenue increased by 26% to $2.47 billion. Service revenue increased by 20%.
- da Vinci procedures grew about 18%, with U.S. general surgery and OUS (outside the U.S.) general surgery leading. Ion procedures grew about 51%, but Ion system placements fell 28% to 195. U.S. bariatric (weight-loss) procedures declined in the high-single digits.
- 1,721 da Vinci systems were placed, including 870 da Vinci 5 systems versus 362 in 2024. Operating lease revenue was $874 million, of which $531 million came from usage-based arrangements that bill per procedure.
- Gross profit as a percentage of revenue was 66.0%, compared to 67.5% in 2024. Management cited new tariffs, higher fixed overhead and depreciation from expanded manufacturing, and higher da Vinci 5 costs. Tariffs and other trade measures increased cost of revenues by approximately $63.0 million.
- Net cash provided by operating activities was $3.03 billion. The company repurchased 4.8 million shares for $2.30 billion and ended the year with $9.03 billion in cash, cash equivalents, and investments.
Risks specific to this company
- China: Fewer systems were placed than anticipated in 2025 because of a government anti-corruption campaign that delayed or canceled hospital tenders, plus domestic competition. Several provinces have also capped what hospitals can charge for robotic surgery, pressuring pricing.
- Tariffs and supply: A significant majority of instruments and accessories are made in Mexicali, Mexico, and most have avoided U.S. tariffs under the USMCA trade agreement. Endoscopes mostly made in Germany and raw materials from China are tariffed. China's export controls on rare earth elements, which are critical to certain components, could disrupt supply.
- Lease and usage exposure: Usage-based leases generally carry no minimum payments, and customers can exit without a penalty. Revenue from them can be volatile, and the company may not recover the cost of a returned system.
- Single-source suppliers: Some components come from sole- or single-sourced suppliers, bought mostly by purchase order rather than long-term agreements. A supplier failure could halt production.
- Litigation and self-insurance: The company faces product liability suits seeking punitive damages, plus antitrust claims from rivals in instruments and servicing and from some customers. It self-insures product liability, so large losses could fall directly on the company.
- Competition and alternatives: Many robotic-surgery rivals are named, including Johnson & Johnson and Medtronic. Third parties also sell remanufactured instruments with FDA clearance, though the filing says the effect has not been material so far.
What management is watching
- Product rollouts: The da Vinci 5 is in a phased launch outside the U.S., with FDA clearance in January 2026 for selected cardiac procedures. The da Vinci SP single-port system is in the early stages of its launch.
- Tariffs and costs: Tariff-driven cost of revenues is expected to rise in 2026 if current tariffs stay in place, and depreciation is also expected to keep increasing.
- Spending: Management expects to keep making substantial research and development investments, which grew 15% in 2025. Capital spending continues on manufacturing facilities and vertical integration of imaging and instrument technology. Purchase commitments total approximately $2.53 billion.
- Ion in the U.S.: Customers' focus is shifting from adding capacity to using existing systems more.
- Measures management points to: Procedure counts, installed base, system utilization (procedures per system per year, up 3%), and recurring revenue, which was 84% of total revenue.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 21, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Intuitive Surgical grew revenue by 22% to $3.05 billion in the third quarter, with procedure volume and system placements both rising. Operating income fell 22% to $592.6 million because of a $450 million charge to settle antitrust class action litigation. Management also laid out instrument price cuts that it expects to lower revenue per procedure.
How the business did
- Revenue: Revenue was $3.05 billion, up from $2.51 billion a year earlier, and rose 21% for the nine months. Instruments and accessories revenue rose 18% to $1.80 billion and systems revenue rose 30% to $769 million. Approximately 906,000 da Vinci procedures were performed, up 14%. Ion procedures grew 31%.
- Placements: 546 da Vinci systems were placed, up 28%, including 315 da Vinci 5 systems. The company said China placements came in below its expectations, citing domestic competition and a government governance campaign that has delayed or canceled tenders.
- Profit: Gross profit as a percentage of revenue was 68.4%, versus 66.4% a year earlier. The filing credits refunds of tariffs paid in prior periods, which reduced cost of revenue by $27.8 million in the quarter. Operating income of $592.6 million compares with $759.7 million a year earlier.
- Cash and capital return: The company repurchased 7.8 million shares for $2.94 billion in the quarter. Cash and investments were $6.80 billion, down from $9.03 billion at December 31, 2025, mainly from buybacks and an acquisition. Operating cash flow for the nine months was $3.20 billion, against net income of $2.17 billion.
What management is watching
- Instrument pricing: Beginning in the fourth quarter of 2026, the company expects price reductions in China tied to a new national pricing framework. In the first half of 2027 it expects longer-life instruments and volume-based pricing. Together these are expected to reduce da Vinci instruments and accessories revenue per procedure by approximately 3% to 5% once fully implemented, and the filing says the result could differ materially.
- Spending: Management expects research and development expenses to keep increasing, and expects depreciation and intangible asset amortization to be higher through the rest of 2026.
- Measures cited: Procedure counts remain the main indicator of adoption and future revenue. The company also points to recurring revenue (instruments, service and operating leases), which was 84% of total revenue. In the U.S., Ion customers are shifting focus from adding capacity to using existing systems more.
New or changed risks
- The filing presents one updated risk factor, on third parties selling remanufactured or unauthorized instruments and accessories. It says some of these have been remanufactured to stretch limited-use instruments beyond their labeled life, may sell at lower prices, and could reduce revenue.
- The same risk factor covers unauthorized service on da Vinci and Ion systems, and warns of patient safety concerns and reputational harm if such products fail.
- It also notes that laws regulating how third-party instruments and service providers interact with the company's systems could hurt the business.
Follow ISRG in Kortex
The Kortex app shows ISRG's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.